Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia,
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
10:37am, Wednesday, 04'th Sep 2024
The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
10:56am, Thursday, 15'th Aug 2024
Seres Therapeutics (MCRB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
03:35pm, Tuesday, 13'th Aug 2024
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Lisa von Moltke - Chief Medical Officer Marel
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
07:00am, Tuesday, 06'th Aug 2024
Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximatel
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
07:00am, Tuesday, 06'th Aug 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and li
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 07'th Jun 2024
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
07:00am, Thursday, 06'th Jun 2024
Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
06:30am, Thursday, 06'th Jun 2024
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performanc
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
05:34pm, Saturday, 11'th May 2024
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2024 Results Conference Call May 8, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Terri Young - Chief Commercial and Strategy Office
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
07:00am, Wednesday, 08'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 06'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compe
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
09:30am, Monday, 06'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
07:00am, Tuesday, 09'th Apr 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 28'th Mar 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Co
